Exploring the Spatial Distribution of mRNA-Lipid Nanoparticles in Mouse Whole-Body and Isolated Organs Using MALDI MSI
To investigate the biodistribution and potential toxicity of lipid nanoparticles (LNP1 and LPN2), which are crucial carriers for mRNA-based treatments after administration to male and female mice, by analyzing their distribution in whole-body carcasses and specific organs using MALDI-MSI.
Download our poster to learn more.
Distribution of Standard-of-Care Antituberculosis Drugs in Cynomolgus Macaque Lungs
The non-human primate (NHP) provides the most clinically relevant model of human tuberculosis. The aim of this study was to determine the tissue pharmacokinetics of orally delivered isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) combination therapy (HRZE) in the lung of cynomolgus macaques to prepare following studies in Mycobacterium tuberculosis-infected animals usinq QMSI.
Download our poster to learn more.
LC/MS/MS Analysis of Coproporphyrin I and Coproporphyrin III in Human Plasma
A bioanalytical assay was developed and validated for the analysis of coproporphyrin I (CP‐I) and coproporphyrin III (CP‐III) in human plasma to assess hepatic OATP1B1/1B3 function. This method uses LC-MS/MS detection to monitor these biomarkers and potentially avoid the need for dedicated clinical drug-drug interaction studies. Download our poster to learn more.
Non-Proprietary Assay (NPA) List
Aliri brings more than 30 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development. We offer an extensive list of validated, off-the-shelf assays you can leverage to support a range of research applications. In addition to the hundreds of assays listed below, Aliri also excels at developing customized methods to meet your specific challenges.
The Importance of Sample Clean up Demonstrated by the Revalidation of the Biomarker 4β-hydroxycholesterol for Assay Robustness
Uncover the advancements reshaping biomarker analysis with our refined method for quantifying 4β-hydroxycholesterol (4β-OHC) – a vital biomarker for CYP3A activity. With our improved assay methodology, we offer a reliable solution for quantifying 4β-OHC, empowering researchers and clinicians with accurate biomarker data for informed treatment decisions.
Download our poster to unlock the potential of this innovative approach.
Validation of an LCMS Hybrid Assay with EVOSEP cleanup for the quantitation of Islet Amyloid polypeptide in human plasma
Delve into the forefront of biomarker analysis with our validated LCMS Hybrid Assay, offering precise quantitation of Islet Amyloid Polypeptide (IAPP) in human plasma. Our method revolutionizes detection by coupling immunoprecipitation from plasma with EVOSEP solid phase extraction and microflow chromatography, resulting in detection limits comparable to traditional methods. By leveraging a high-binding, non-specific antibody for IAPP, our assay surpasses commercially available kits, ensuring comprehensive analysis of different IAPP forms.
Download our poster to discover the innovation behind our approach and its potential uses in regulated settings and biologics advancement.
Tissue Adenosine Distribution-Guided Gene Selection for the Development of a Composite Biomarker in Immuno-Oncology Therapy
Discover the groundbreaking approach revolutionizing Immuno-Oncology (IO) therapy through tissue adenosine distribution-guided gene selection for composite biomarker development. Our method transcends traditional predictive biomarkers by integrating spatial metabolomics and genomics, offering a comprehensive strategy to predict patient responses to IO therapies.
Download our poster to explore the transformative potential of adenosine-driven gene signatures in personalized cancer treatment strategies.
Multimodal stratification of predictive biomarkers in head and neck cancers: A focus on cytokine-based immunotherapy
Explore our recent poster presentation, which discusses the challenge of identifying predictive biomarkers for cytokine-based immunotherapy in head and neck cancers due to the complexity of biological systems and cancer pathophysiology. It highlights the importance of understanding how drugs interact with different biomarkers and tissues spatially to improve trial success rates, reduce costs, and accelerate completion times.
By analyzing spatial and temporal changes in tumor cells and their microenvironment, you can uncover resistance mechanisms, leading to the design of more effective combination therapies. The Aliri solution offers enhanced tumor profiling through spatial analysis, integration of heterogenous data types, and predictive analysis, ultimately identify robust biomarker signatures for improved immunotherapy outcomes.
Download our poster to gain insights into the unique biomarker signatures correlated with therapy response.
CONTACT US to learn more about Aliri’s extensive experience with this technology.
Keeping an eye on molecular imaging: drug efficacy & toxicity in ophthalmology
Discover how Mass Spectrometry Imaging (MSI) is revolutionizing preclinical studies by offering quick and accurate assessments of ocular treatments’ efficacy and safety.
With MSI, track the bio-distribution of drugs and metabolites while pinpointing biomarkers for efficacy or toxicity. Gain valuable insights into ocular drug distribution and biomarker modulation with Aliri’s advanced MSI technology.
Download our application note to dive deeper into our MSI technology and its applications in ocular diseases.
Coproporphyrin-I and Coproporphyrin-III
Aliri Bioanalysis presents a newly validated non-proprietary biomarker assay (NPA) for the quantitation of Coproporphyrin I and Coproporphyrin III in human plasma. This assay offers significant advancements in biomarker analysis, applicable across diagnostics, pharmaceutical research, and patient care.
By monitoring these biomarkers, particularly in early clinical development, companies can assess OATP1B1 inhibition, potentially avoiding the need for dedicated clinical drug-drug interaction studies, saving both time and money.
Learn more about the benefits of our NPA for Coproporphyrin I and Coproporphyrin III.